Kodiak Sciences (KOD) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$1.05

Estimate

-$0.96

Surprise

-9.8%

Score today

5.0/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Kodiak Sciences (KOD) reported a wider loss than forecast — diluted EPS of -$1.05 against the -$0.96 estimate (a 9.8% shortfall).

• Kodiak Sciences Q2 EPS $(1.05) Misses $(0.95) Estimate — benzinga, 2026-08-13

TrendMatrix currently rates KOD Sell at 5.0/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -9.8% surprise compares with a -3.3% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$33.54

Price target

$60.55

Stop

$31.34

Upside to target

+80.5%

Reward-to-risk

7.3:1

Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.07B

P/E (fwd)

-8.8

52-week range

$9.10–$47.84

Off 52-week high

29.9%

RSI (14)

25

Volume vs avg

1.14×

Score today

5.0/10